首页> 外文期刊>Clinical and vaccine immunology: CVI >Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice
【24h】

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice

机译:保守的NP,PB1和M1蛋白作为基于DNA和痘苗病毒的通用A型流感病毒疫苗在小鼠中的免疫原的保护功效

获取原文
           

摘要

The conventional hemagglutinin (HA)- and neuraminidase (NA)-based influenza vaccines need to be updated most years and are ineffective if the glycoprotein HA of the vaccine strains is a mismatch with that of the epidemic strain. Universal vaccines targeting conserved viral components might provide cross-protection and thus complement and improve conventional vaccines. In this study, we generated DNA plasmids and recombinant vaccinia viruses expressing the conserved proteins nucleoprotein (NP), polymerase basic 1 (PB1), and matrix 1 (M1) from influenza virus strain A/Beijing/30/95 (H3N2). BALB/c mice were immunized intramuscularly with a single vaccine based on NP, PB1, or M1 alone or a combination vaccine based on all three antigens and were then challenged with lethal doses of the heterologous influenza virus strain A/PR/8/34 (H1N1). Vaccines based on NP, PB1, and M1 provided complete or partial protection against challenge with 1.7 50% lethal dose (LD50) of PR8 in mice. Of the three antigens, NP-based vaccines induced protection against 5 LD50 and 10 LD50 and thus exhibited the greatest protective effect. Universal influenza vaccines based on the combination of NP, PB1, and M1 induced a strong immune response and thus might be an alternative approach to addressing future influenza virus pandemics.
机译:常规的基于血凝素(HA)和神经氨酸酶(NA)的流感疫苗需要更新大多数年,如果疫苗株的糖蛋白HA与流行株的糖蛋白HA不匹配,则这种疫苗无效。靶向保守病毒成分的通用疫苗可能提供交叉保护,从而补充和改进常规疫苗。在这项研究中,我们从流感病毒株A / Beijing / 30/95(H3N2)产生了表达保守蛋白核蛋白(NP),聚合酶碱性1(PB1)和基质1(M1)的DNA质粒和重组牛痘病毒。用单独基于NP,PB1或M1的单一疫苗或基于所有三种抗原的联合疫苗对BALB / c小鼠进行肌肉内免疫,然后用致死剂量的异源流感病毒A / PR / 8/34进行攻击( H1N1)。基于NP,PB1和M1的疫苗在小鼠体内提供了针对1.7 50%致死剂量(LD 50 )的PR8的完全或部分保护,以抵抗攻击。在这三种抗原中,基于NP的疫苗可诱导针对5 LD 50 和10 LD 50 的保护,因此发挥了最大的保护作用。基于NP,PB1和M1组合的通用流感疫苗可诱导强烈的免疫反应,因此可能是应对未来流感病毒大流行的另一种方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号